PharmaTalkRadio

Épisodes

• 
  What to Expect at Partnerships with Sites 2026 14.07.2026 5min
• 
  Unlocking Unstructured Data with AI for Optimized Protocol Development 02.06.2026 24min

  In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.  More specifically, Mike discusses:  How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments What questions sponsors should be asking of AI vendors, to pick the correct partner How sponsors have responded to the insights surfaced by this technology  Why sponsors must adapt to a flexibility mindset in order to truly make changes with downstream impact 
• 
  Bridging Access Gaps: Sponsor-Led Enablement of Research-Naïve Sites to Expand Patient Reach 08.05.2026 23min

  Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach.How naïve sites can help address access and enrollment bottlenecksHow to support inexperienced sites with the right sponsor-led infrastructureWhat it takes to shift internal expectations and foster lasting site partnershipsSpeakers:Carrie Lewis Executive Director, Clinical Program Optimization, EndoSuzy Montayne Site Relationship Manager, EndoTerry Oehler, DPM Founder & CEO, Colorado Clinical Research
• 
  Building Trust-Driven Partnerships: AstraZeneca’s Concierge Approach to Accelerating Site Activation and Enrollment 08.05.2026 21min

  AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by real metrics and lessons learned from a three-year initiative. Key topics include:How continuous site feedback loops and flexibility with SOPs improved startup timelinesMetrics from a recent study showing impact: 30% faster budget negotiations, 27% reduced activation times, 68% of recruitment from 42% of sitesTools and tactics used to build consistency, transparency, and trust across studiesLessons learned and how the program has scaled globallySpeakers:Shannon Edwards Site Engagement Lead, AstraZenecaTina Nghiem Site Engagement Lead, AstraZeneca
• 
  Eli Lilly on Site Enablement: Co-Designing Solutions with Sites 08.05.2026 43min

  A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency.Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & CoModerator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Center
• 
  What a Strategic Partnership Looks Like in Practice: Inside the Takeda–Basil Collaboration That Delivered Tenfold Enrollment 08.05.2026 20min

  This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible.Identifying and partnering with highpotential sitesIncorporating site feedback and early collaboration to improve trial executionBuilding trust and fostering long-term site relationshipsKey actions that led to exceptional enrollment and trial efficiencySpeakers:Brandon Doyle, MBA Associate Director, Study Site Engagement, Takeda Mark Rapp, MD Principal Investigator, Basil Clinical Research
• 
  Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain 05.05.2026 29min

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherenceHow pharma can use drug delivery device data with predictive analytics to forecast demand and optimize productionEnabling patient-centric design and innovation by analyzing device usage dataTo learn more about the PODD Conference, please visit PODDConference.com.
• 
  Ensuring Sustainability Throughout Drug and Device Development 05.05.2026 28min

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:How pharma and suppliers can improve sustainabilityCreating designs with lower carbon footprints relative to fabrication and materialsCircular recycling modelsTo learn more about the PODD Conference, please visit PODDConference.com.
• 
  Utilizing AI to Facilitate Combination Product Development 05.05.2026 29min

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years.To learn more about the PODD Conference, please visit PODDConference.com.
• 
  Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success 05.05.2026 29min

  Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling.To learn more about the PODD Conference, please visit PODDConference.com.
• 
  Advances and Opportunities in Dual Chamber Injectables 05.05.2026 27min

  In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: Overcoming primary container and autoinjector challenges for liquid-liquid deliveryImproving upon dual chamber reconstitution devicesFinding the right approach to navigate supply chainTo learn more about the PODD Conference, please visit PODDConference.com.
• 
  How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma 24.02.2026 27min

  About this Podcast: As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI.More specifically, Sean discusses:  Separating short-term, mid-term and long-term costs and benefits of implementing AI What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI AI deployed for bottom-line revenue versus internal team efficiency What the first steps would be for sponsors to successfully integrate AI across their enterprise 
• 
  How Bayer Reorganized Their Clinical Operations Structure for Efficiency and Cost Savings 29.01.2026 12min

  About this podcast:Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. Dr Glombitza details the results of the change thus far, including significant increases in efficiency and reduction in cost, maintaining quality levels and study targets, and improving employee job satisfaction. 
• 
  How Amicus Embedded Patient Advocacy into its Corporate DNA 29.01.2026 25min

  About this podcast:In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.More specifically, Ms Gershkowitz focuses on:Defining role standards and recruiting the right talent Co-creatin research with patient communities and developing patient-centered outcomesGenerating metrics that demonstrate the impact on R&D
• 
  Designing Clinical Trials Balancing Simplicity with Complexity 27.01.2026 30min

  When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials.More specifically:Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplicationDesigning trials around real patients rather than ideal patientsBetter understanding the objectives of the study and asking the questions that achieve those objectivesBetter partnering with patients and PIsTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.
• 
  Platform Approaches to Streamline Combination Product Development 27.01.2026 30min

  Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: Advantages and disadvantages to platform approaches for device developmentOpportunities to overcome technical limitationsApproaches to bring a platform into multiple product design history filesRegulatory hurdlesAssessing business case and getting organizational buy-inTo learn more about the PODD Conference, please visit Drug-Delivery.org.
• 
  What is the State of Clinical Trial Patient Matching Right Now? 19.12.2025 40min

  About this podcast:Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss: Different models and the pros and cons of the deployment modelsWhat makes a great patient matching solutionPredicting what the future growth of this segment looks likeThe role of AI in this space
• 
  Balancing Innovation and Practicality in Immuno-Oncology Dose Selection 19.12.2025 45min

  About this podcast: Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies. For more information, go to IO360summit.com.
• 
  Leveraging Local HCPs to Decentralize Clinical Research in North Carolina 19.12.2025 20min

  About this podcast: Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares  an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed if they’re only performing standard-of-care. Dr J Kaitlin Morrison talks about the process from an initial pilot of two sites to more than 23 today, providing cancer patients across the state the opportunity to access clinical trials. Specifically:How they are managing relationships with sitesHow they’re monitoring research elementsGoals, next steps and thoughts for industry sponsors
• 
  Using Patient Engagement and Digital Innovation to Elevate Patient Insights and Outcomes 19.12.2025 19min

  About this podcast:This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. For more information, go to theconferenceforum.org.